Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study
机构：[1]Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China[2]Hebei Med Univ, Breast Ctr, Hosp 4, Shijiazhuang, Hebei, Peoples R China临床科室外一科河北医科大学第四医院[3]Jiangxi Canc Hosp, Breast Surg, Nanchang, Jiangxi, Peoples R China[4]Hunan Canc Hosp, Changsha, Peoples R China[5]Qingdao Univ, Breast Dis Ctr, Affiliated Hosp, Qingdao, Peoples R China[6]Tianjin Med Univ, Breast Med Oncol, Canc Inst & Hosp, Tianjin, Peoples R China[7]Peking Univ, Dept Breast Ctr, Peoples Hosp, Beijing, Peoples R China[8]Chongqing Med Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 1, Chongqing, Peoples R China重庆医科大学附属第一医院[9]Yuncheng Cent Hosp, Breast Ctr, Yuncheng, Peoples R China[10]Zhejiang Univ, Breast Surg, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
第一作者机构：[1]Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Yang Benlong,Geng Cuizhi,Sun Zhengkui,et al.Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA：
Yang, Benlong,Geng, Cuizhi,Sun, Zhengkui,Ouyang, Quchang,Wang, Haibo...&Wu, Jiong.(2024).Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA：
Yang, Benlong,et al."Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)
医学